<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; TrueBlue</title>
	<atom:link href="http://www.stockbloghub.com/tag/trueblue/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(TBI) Initiating Oxygen Biotherapeutics at Outperform Rating</title>
		<link>http://www.stockbloghub.com/2009/10/26/tbi-initiating-oxygen-biotherapeutics-at-outperform-rating/18730</link>
		<comments>http://www.stockbloghub.com/2009/10/26/tbi-initiating-oxygen-biotherapeutics-at-outperform-rating/18730#comments</comments>
		<pubDate>Mon, 26 Oct 2009 22:45:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Services]]></category>
		<category><![CDATA[Staffing & Outsourcing Services]]></category>
		<category><![CDATA[TBI]]></category>
		<category><![CDATA[TrueBlue]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18730</guid>
		<description><![CDATA[We are initiating coverage of Oxygen Biotherapeutics, Inc. (OXBO) with an ‘Outperform’ rating. Despite what has been a tumultuous past for the company and a abysmal fate for competitors attempting to develop similar products, the potential upside that Oxycyte offers is too significant to ignore. Does Oxycyte do what management says it does? (Key Efficacy Question) In theory, Oxycyte has the potential to be a wonder drug &#8212; a sort of WD-40 of medicine. Preclinical data suggests that Oxycyte has astounding potential for the treatment of traumatic brain injury (TBI), decompression sickness, carbon monoxide poisoning, sickle cell crisis, organ preservation and as a neuroprotectant in patients with myocardial infarction or stroke. The effects in TBI were clearly evident in the phase I program conducted by Oxygen Bio in 2006. Initial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/26/tbi-initiating-oxygen-biotherapeutics-at-outperform-rating/18730/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

